open access

Vol 69, No 5-6 (2019)
Short review
Get Citation

Should perioperative chemotherapy in triple negative breast cancer routinely comprise platinum salts? A vote for no

Joanna Kufel-Grabowska
DOI: 10.5603/NJO.2019.0035
·
Nowotwory. Journal of Oncology 2019;69(5-6):182-183.

open access

Vol 69, No 5-6 (2019)
Short review

Abstract

Breast cancer is the most common female neoplasm in Poland and worldwide, its mortality rate ranking second only to lung cancer. There are several biological subtypes, differing, among other parameters, as to prognosis and perioperative treatment recommendations. Triple negative breast cancer is one of the worst prognoses and systemic preoperative treatment is recommended as early as of II TNM stage. Pathological complete response (pCR) may result in an improved prognosis. Most patients respond well to standard chemotherapy and there is no need to include platinum derivatives in perioperative therapies. One should remember that platinum salts use not only increases the percentage of pCRs, but also results in an increased therapeutic toxicity; it does not, however, have an impact on disease free survival (DFS) an overall survival (OS).

Abstract

Breast cancer is the most common female neoplasm in Poland and worldwide, its mortality rate ranking second only to lung cancer. There are several biological subtypes, differing, among other parameters, as to prognosis and perioperative treatment recommendations. Triple negative breast cancer is one of the worst prognoses and systemic preoperative treatment is recommended as early as of II TNM stage. Pathological complete response (pCR) may result in an improved prognosis. Most patients respond well to standard chemotherapy and there is no need to include platinum derivatives in perioperative therapies. One should remember that platinum salts use not only increases the percentage of pCRs, but also results in an increased therapeutic toxicity; it does not, however, have an impact on disease free survival (DFS) an overall survival (OS).

Get Citation

Keywords

breast cancer; triple negative breast cancer; perioperative therapy; platinum salts

About this article
Title

Should perioperative chemotherapy in triple negative breast cancer routinely comprise platinum salts? A vote for no

Journal

Nowotwory. Journal of Oncology

Issue

Vol 69, No 5-6 (2019)

Pages

182-183

DOI

10.5603/NJO.2019.0035

Bibliographic record

Nowotwory. Journal of Oncology 2019;69(5-6):182-183.

Keywords

breast cancer
triple negative breast cancer
perioperative therapy
platinum salts

Authors

Joanna Kufel-Grabowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl